NYSEAMERICAN:NSRX Nasus Pharma Q2 2026 Earnings Report $3.48 0.00 (0.00%) Closing price 09/25/2026 04:10 PM EasternExtended Trading$3.44 -0.04 (-1.18%) As of 09/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nasus Pharma EPS ResultsActual EPS-$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANasus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANasus Pharma Announcement DetailsQuarterQ2 2026Date8/17/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Nasus Pharma Earnings HeadlinesNasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical PipelineSeptember 18, 2026 | tipranks.comNasus Pharma's IND Application For NS002 Gets FDA ClearanceSeptember 14, 2026 | rttnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 27 at 1:00 AM | Altimetry (Ad)Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis TrialSeptember 14, 2026 | tipranks.comNasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisSeptember 14, 2026 | globenewswire.comNasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | quiverquant.comQSee More Nasus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nasus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nasus Pharma and other key companies, straight to your email. Email Address About Nasus PharmaNasus Pharma (NYSEAMERICAN:NSRX) is an Israel-based specialty pharmaceutical company focused on developing intranasal treatments for acute medical conditions. The company’s platform is designed to deliver drug powders through the nose, with the goal of offering convenient, needle-free alternatives to certain injectable therapies. Nasus Pharma’s development activities center on intranasal pharmaceutical products intended for rapid administration in emergency and urgent-care settings. Its pipeline has included candidates targeting conditions in which fast drug delivery may be important, although the availability and development status of individual products may change as clinical and regulatory work progresses. The company conducts its research and development activities in Israel and is seeking to advance its intranasal drug-delivery technology for potential use in international markets. Nasus Pharma’s shares trade on the NYSE American under the symbol NSRX.View Nasus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
